Financial Performance - BioLife Solutions, Inc. announced preliminary unaudited revenue for Q4 2025 and the full year ended December 31, 2025[4]. - The report does not provide specific revenue figures or growth percentages in the available content[4]. Compliance and Reporting - The report was filed on January 12, 2026, indicating the company's compliance with the Securities Exchange Act of 1934[4]. - The company has not elected to use the extended transition period for complying with new financial accounting standards[3]. - The financial results will not be deemed "filed" under the Exchange Act, limiting liability under Section 18[5]. - The Chief Financial Officer, Troy Wichterman, signed the report, indicating executive oversight[10]. Company Information - The company is listed on the Nasdaq Stock Market under the trading symbol BLFS[2]. - The company operates from its headquarters located at 3303 Monte Villa Parkway, Bothell, WA[2]. Additional Information - The press release detailing the financial results is attached as Exhibit 99.1[6]. - No information on new products, technologies, market expansion, or mergers and acquisitions was provided in the current report[4].

Revenue and Growth - Revenue for Q4 2025 was $120.9 million, representing a 13% increase compared to Q4 2024[4] - Total revenue for Q4 2025 was $120.887 million, up from $107.090 million in Q4 2024, representing a year-over-year growth of approximately 12.5%[43] - For the full year 2025, total revenue was $457.547 million, compared to $405.908 million in 2024, marking a year-over-year increase of approximately 12.7%[47] - Subscription revenue for Q4 2025 reached $118.504 million, compared to $105.922 million in Q4 2024, indicating a growth of about 11.8%[43] - The approximated TTM subscription revenue contribution for customers contributing $30,000 or more in ARR was $268.0 million, accounting for 59.1% of total subscription revenue[7] Customer Metrics - The number of customers contributing $30,000 or more in ARR grew to 3,803, an increase of 13% compared to the previous year[10] - The number of customers contributing $30,000 or more in ARR is viewed as a key metric for future growth potential[32] - The dollar-based net retention rate was 100% in 2025, down from 104% in 2024[10] - The dollar-based net retention rate was not explicitly stated, but the company emphasizes its importance in evaluating long-term customer relationships[34] Profitability and Income - Non-GAAP operating income was $11.5 million, slightly up from $11.4 million in Q4 2024[4] - Non-GAAP net income was $11.6 million, compared to $10.7 million in Q4 2024[4] - Non-GAAP net income for the twelve months ended December 31, 2025, was $48,237 thousand, compared to $28,633 thousand in 2024, an increase of 68.5%[58] - Non-GAAP net loss per share for Q4 2025 was $0.18, compared to $0.25 in Q4 2024, showing a decrease of 28%[44] Expenses and Losses - The net loss for Q4 2025 was $10.741 million, an improvement from a net loss of $14.417 million in Q4 2024, reflecting a reduction of approximately 25.5%[44] - Total operating expenses for Q4 2025 were $104.573 million, up from $97.354 million in Q4 2024, which is an increase of about 7.5%[44] - Stock-based compensation expense for the full year 2025 totaled $78.719 million, down from $84.303 million in 2024, reflecting a decrease of approximately 6.0%[47] - Stock-based compensation expense for the twelve months ended December 31, 2025, was $78,719 thousand, down from $84,303 thousand in 2024, a decrease of 6.7%[56] Cash and Assets - Cash and cash equivalents totaled $95.3 million as of December 31, 2025, up from $90.6 million as of September 30, 2025[4] - The company reported a net increase in cash, cash equivalents, and restricted cash of $6,785 thousand for the twelve months ended December 31, 2025[56] - Total assets increased to $523,062 thousand in 2025 from $428,341 thousand in 2024, representing a growth of 22.1%[49] - Current assets rose to $237,204 thousand in 2025, up from $210,215 thousand in 2024, an increase of 12.9%[49] - Total stockholders' equity increased to $203,422 thousand in 2025, compared to $166,594 thousand in 2024, reflecting a growth of 22.1%[50] Future Outlook - The company aims for a non-GAAP operating margin of approximately 15% by Q4 2026 and a 30% target for the Rule of 40 framework by Q4 2027[12] - The company expects total revenue for Q1 2026 to be between $119.9 million and $120.7 million[9] Deferred Revenue and Goodwill - Deferred revenue increased to $205,639 thousand in 2025 from $178,585 thousand in 2024, a rise of 15.2%[49] - Goodwill increased significantly to $167,122 thousand in 2025 from $121,315 thousand in 2024, a rise of 37.8%[49]

Exhibit 99.1 Zscaler Announces Strong Second-Quarter Fiscal 2026 Results; Raises Fiscal 2026 ARR Guidance to 24% Exceeds high-end of second-quarter guidance on revenue and profitability metrics Second Quarter Highlights SAN JOSE, California - February 26, 2026 - Zscaler, Inc. (Nasdaq: ZS), the leader in cloud security, today announced financial results for its second quarter of fiscal year 2026, ended January 31, 2026. "We believe Zscaler is the cybersecurity platform for the AI age - our in-line Zero Trust ...

MIAMI, February 26, 2026 – OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: • Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regene ...

Operating Results (Unaudited) | | Three Months Ended | | | | | Year Ended | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | December 31, | | December 31, | | December 31, | | December 31, | | | (Millions of Dollars Unless Otherwise Stated) | 2025 | | 2024 | | 2025 | | 2024 | | | GAAP Net Income (Loss) Attributable to Stockholders | $ $ | (363) | | 82 $ | $ | (219) | | 998 | | Adjusted EBITDA | | 382 | | 164 | | 1,035 | | 770 | | Adjusted Free Cash Flow | | 292 | | 21 | | 524 | | 283 | | (a) ...

Exhibit 99.1 Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – February 26, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. Fourth Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310; ETV:IDS) for Hunter syndrome (mucopolysaccharidosis type II [MPS II]) Denali has es ...

COMPANY CONTACTS Briony Quinn Chief Financial Officer (240) 744-1196 Dori Kesten Capital Markets (617) 835-8366 DIAMONDROCK HOSPITALITY COMPANY REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS Comparable Total RevPAR Growth, Adjusted EBITDA, and Adjusted FFO Per Share Exceed High End of Guidance BETHESDA, Maryland, Thursday, February 26, 2026 – DiamondRock Hospitality Company (Nasdaq: DRH, the "Company"), a lodging real estate investment trust that owns a portfolio of 35 premium hotels and resorts in the U ...

Exhibit 99.1 Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance Business Highlights: Financial Results: Full Year 2026 Guidance: WILMINGTON, Del. – February 26, 2026 – Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the fourth quarter and full year 2025. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights. "Our ...

Financial Performance - FY 2025 revenue was $282.9 million, a decrease from $291.3 million in FY 2024[6] - Adjusted EBITDA for FY 2025 was $61.6 million, representing a 22% margin, down from $92.3 million and 32% margin in FY 2024[6] - Fourth quarter revenue was $80.0 million, compared to $85.5 million in Q4 2024[12] - GAAP net income for Q4 2025 was $6.7 million, down from $13.9 million in Q4 2024[12] - Gross profit for the year ended December 31, 2025, was $179,841,000, down from $190,229,000 in 2024, reflecting a decline of 5.5%[34] - Net loss for the year ended December 31, 2025, was $(14,462,000), compared to a net income of $12,504,000 in 2024[34] - Operating income for Q4 2025 was $8,524,000, down from $14,802,000 in Q4 2024, representing a decline of 42.2%[34] - Revenue for Q4 2025 was $80,046, a decrease from $85,502 in Q4 2024, with total revenue for 2025 at $282,926 compared to $291,256 in 2024[39] - Adjusted EBITDA for Q4 2025 was $27,818, down from $37,646 in Q4 2024, with a full year adjusted EBITDA of $61,640 for 2025 compared to $92,325 in 2024[39] - Non-GAAP net income for Q4 2025 was $14,440, compared to $21,443 in Q4 2024, with full year non-GAAP net income of $16,701 for 2025 versus $42,452 in 2024[39] Cash Flow and Assets - Free cash flow in FY 2025 was $46.2 million, an increase of 32% over FY 2024[6] - Total cash, cash equivalents, and marketable securities at the end of FY 2025 were $145.5 million, a 4% increase from FY 2024[6] - Cash and cash equivalents increased to $145,518,000 in 2025 from $100,452,000 in 2024, an increase of 44.8%[32] - Net cash provided by operating activities for Q4 2025 was $18,159, slightly up from $18,048 in Q4 2024, with total operating cash flow for 2025 at $81,059 compared to $73,425 in 2024[41] - Free cash flow for Q4 2025 was $6,852, down from $8,856 in Q4 2024, with total free cash flow for 2025 at $46,203 compared to $34,897 in 2024[41] Shareholder Actions - The company repurchased 4.1 million shares in 2025, representing 8.1% of fully diluted shares[1] - Total stock-based compensation for 2025 was $38,378, compared to $37,676 in 2024, indicating a slight increase in compensation expenses[39] Future Guidance - For Q1 2026, revenue is expected to be between $58 million and $60 million, with adjusted EBITDA guidance of $(0.5) million to $1.0 million[23] - The company expects to provide guidance for revenue and adjusted EBITDA for Q1 2026, indicating a focus on future growth[28] Market Performance - CTV revenue grew over 50% year-over-year in FY 2025, excluding political ad spend[17] - Net dollar-based retention rate for FY 2025 was 96%, indicating strong publisher satisfaction[6] Innovation and Strategy - The company continues to innovate in programmatic advertising, leveraging AI-driven optimization and privacy-focused solutions[29]

Exhibit 99.1 • Revenue grew 10.2% to $931.8 million, approximately 10.9% on a constant currency basis • GAAP Net Income attributable to common shareholders was $141.6 million an increase of 25.7%, or $2.20 per diluted share • Adjusted EBITDA was $373.4 million an increase of 9.7% and Adjusted earnings per common share increased by 10.4% to $3.62 • $82.1 million returned to shareholders through share repurchases and dividends • Increased and extended share repurchase program EVERTEC REPORTS FOURTH QUARTER AN ...